Biophysical and chemical properties are critical factors that can dictate success or failure in the development of therapeutic antibodies. These attributes and all the functional characteristics of antibodies depend on amino acid sequence, post-translational modifications, and the solution environment. Early quality control and risk assessment of biophysical parameters help prevent failure in later stages of antibody development. An early-stage developability workflow was designed to set stage gate for molecules progressing to late-stage development. Application of the Uncle platform in antibody selection will be presented in this webinar. Stability analysis of engineered antibody variants was evaluated using Intrinsic Fluorescence Conformational Stability (T_m) and Colloidal Stability (T_agg). B₂₂/k_D parameters for monoclonal antibodies (mAbs) in solution were determined and validated by Small-Angle-X ray-scattering (SAXS). Quantitative correlation between T_agg and particle size for mAbs was observed in this study.

Who Should Attend

• Researchers developing monoclonal antibodies
• Drug discovery scientists
• Investigators interested in biologic stability
• Biochemists
• QC/QA scientists

You Will Learn

• How to use T_m and T_agg measurements to evaluate the stability of engineered antibodies
• How the aggregation propensity parameters B₂₂ and k_D can help further evaluate antibody variants
• How the Uncle platform can collect multiple measurements earlier, with less sample

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.